The aggregate annual economic impact included $5.5 billion spent for medical care and the value of informal care as well as a loss of more than 20,9000 quality-adjusted life years.
Relevant Methodology
Medical Expenditure Panel Survey data from 1996 to 2002 were pooled to estimate the relationship of visual impairment and blindness with total medical expenditures, components of expenditures, days of informal care received, and health utility. Estimates accounting for the complex sampling design were based on regressions including confounders such as comorbidities and demographics. The aggregate economic impact was estimated by projecting average individual effects to the population of individuals with blindness and visual impairment.
Outcome Measures
Total healthcare expenditures, excess informal care days, and health utility loss.
Results
Blindness and visual impairment were significantly associated with higher medical care expenditures, a greater number of informal care days, and a decrease in health utility. The home care component of expenditures was most affected by blindness. The aggregate annual economic impact included $5.5 billion spent for medical care and the value of informal care as well as a loss of more than 20,9000 quality-adjusted life years.
Conclusions
Visual impairment has a huge effect on home care. Any economic analysis of prevention, treatment, and rehabilitation should account for the fraction of the annual monetary cost and loss of quality-adjusted life years that can be averted.
blindness are enormous. On the basis of their analysis using multiyear data from a nationally representative survey, the authors report that excess medical care expenditures related to visual impairment and blindness in the United States totaled $5.1 billion in 2004. Moreover, they estimate monetary values of $360 million, and $10.5 billion, respectively, for the provision of informal care and the reduction of quality of life associated with vision loss among the patients. In all, they report the total aggregate economic impact of vision impairment and blindness to the patients and their caregivers and other healthcare payers is almost $16 billion.
Earlier this year, Prevent Blindness America (PBA), the organization funding this research, presented findings from Frick and coworkers' research and results of a complementary analysis by Rein and coworkers that estimated the annual cost of vision impairment to the US economy.
1,2 PBA reported that taken together, these 2 studies indicate that ''the annual cost of adult vision problems in the US comes to approximately $51.4 billion.'' 2 Given the aging of the US population and the fact that the lifespan of the average American is gradually increasing, one would expect these cost estimates to rise considerably in the coming decades. Thus, such efforts to quantify the economic effects of vision impairment and blindness, and to educate policymakers deciding how to allocate limited healthcare resources are critically important. Hopefully, the findings from these and other economic evaluations will serve as an impetus for legislators to direct more resources toward research aimed at identifying ways to prevent and treat vision loss. Furthermore, as the authors wisely point out, when faced with the daunting task of deciding whether to fund proposals aimed at preventing or treating ocular diseases that cause vision loss, decision-makers should consider not only the estimated costs of implementing such programs but also the potential savings to society that can be achieved if these initiatives can successfully reduce vision loss and blindness.
This study was also useful because it helps us appreciate the tremendous costs of home healthcare (through an agency or by a private, independent provider) and informal care (unpaid care provided by friends or family not residing in the patients' household) necessitated by the individuals' blindness or visual impairment. Ideally, adults who require some sort of daily or other assistance because of their blindness or severe visual impairment should be able to access care that best preserves their dignity and sense of well-being without being cost prohibitive. The authors astutely note that although home healthcare associated with blindness or visual impairment costs thousands of dollars annually per patient, efforts should be made, when appropriate, to keep such individuals out of nursing homes and assisted living facilities, which typically are significantly even more expensive than care provided in the community.
As the authors acknowledge, this study has a few limitations, including a reliance on self-reported data to classify survey participants as blind, visually impaired, or fully sighted. In addition, the researchers could not estimate costs for vision-related productivity loss; for this reason, they have probably underestimated the full economic impact of blindness and vision impairment. Overall, however, this economic evaluation contributes greatly to a growing body of literature that may ultimately help secure much-needed funding and other resources to directly or indirectly benefit our patients.
